27/10/2023 - AMOEBA : 2023 Interim Financial Report

Press release

AMOEBA: 2022 Interim Financial Report

Chassieu (France), October 18, 2027 - 17h45 - AMOÉBA (FR0011051598 - ALMIB) an industrial biotech in pre-commercialization*specialised in the treatment of microbiological risk, developing a biocontrol agent for the crop treatment in agriculture that has obtained a marketing authorization in the United States and a biological biocide that has also obtained a marketing authorisation in the United States for use in closed cooling systems, announces the publication of its Interim Financial Report for 2023.

AMOEBA's shareholders are informed that the interim financial report for the 2023 financial year (ending on December 31st, 2023), filed today with the Autorité des Marchés Financiers (AMF), can be found at the company website: https://amoeba-nature.com/en/investor/financial-documents/.

This report includes:

• Interim Activity Report
• Condensed Interim Financial Statements
• Certification of the person responsible for the interim financial report
• Statutory Auditors' Review Report on the interim financial information

About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba Willaertia magna C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €3 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). The commercialization of the associated biocides and phytosanitary products is subject to local regulatory approvals.

*At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a pre-commercialization phase for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010 and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

(1): Amoéba data

Adress : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU	Tel: [phone] - Email: [e-mail]
Société Anonyme au capital de 993 199,26 €	LinkedIn: @amoeba-nature - Twitter: @AmoebaNature
RCS Lyon 523 877 215	www.amoeba-nature.com

(2): IBMA data

(3): Amoeba data

Contacts:
Amoéba	Calyptus
Jean-François DOUCET	Investor & Press Relations
Deputy General Manager	Nicolas HELIN / Mathieu CALLEUX
[phone]	+33 1	53 65 37 90 /91
[e-mail]	[e-mail]

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 18, 2023 under number D23-0296 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of AMOEBA to be materially different from such forward- looking statements.

Adress : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU	Tel: [phone] - Email: [e-mail]
Société Anonyme au capital de 993 199,26 €	LinkedIn: @amoeba-nature - Twitter: @AmoebaNature
RCS Lyon 523 877 215	www.amoeba-nature.com